February 4, 2025
NSE: JBCHEPHARM
J.B. Chemicals & Pharmaceuticals reported robust financial performance for Q3 FY25, with a healthy revenue increase driven by strong domestic and export demand.
Financial Highlights (Standalone)
| Metric | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹91,351 Lakhs | ₹95,576 Lakhs | ₹80,010 Lakhs | ₹2,82,158 Lakhs | ₹2,48,944 Lakhs |
| Net Profit | ₹15,639 Lakhs | ₹17,312 Lakhs | ₹12,792 Lakhs | ₹50,274 Lakhs | ₹41,751 Lakhs |
| Earnings Per Share (Basic) | ₹10.06 | ₹11.15 | ₹8.25 | ₹32.38 | ₹26.95 |
| Interim Dividend | ₹8.5 per share | - | - | - | - |
Key Developments
- Declared an interim dividend of ₹8.5 per equity share.
- Increased employee benefit expenses due to equity-settled share-based payment transactions.
- Continued expansion in the pharmaceutical segment, with strong performance across domestic and international markets.